Compare BHE & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHE | PHVS |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 1.8B |
| IPO Year | 1996 | 2020 |
| Metric | BHE | PHVS |
|---|---|---|
| Price | $84.62 | $30.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $55.00 | $41.82 |
| AVG Volume (30 Days) | ★ 416.9K | 355.8K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $2,659,108,000.00 | N/A |
| Revenue This Year | $7.03 | N/A |
| Revenue Next Year | $6.57 | N/A |
| P/E Ratio | $235.91 | ★ N/A |
| Revenue Growth | ★ 0.11 | N/A |
| 52 Week Low | $34.44 | $15.93 |
| 52 Week High | $89.40 | $33.33 |
| Indicator | BHE | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 51.94 |
| Support Level | $79.49 | $24.73 |
| Resistance Level | $87.71 | $31.14 |
| Average True Range (ATR) | 3.16 | 1.47 |
| MACD | -0.81 | -0.13 |
| Stochastic Oscillator | 52.47 | 32.80 |
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.